4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow PCV20: new trials by email Literature Review of PCV20 trials Research Report on PCV20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination 31-valent pneumococcal conjugate vaccine, PCV20 - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 752 | 2026-02-09 | 2026-11-13 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 4049 | 2025-12-01 | 2026-10-16 |
| Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults RSVPreF3 OA investigational vaccine, PCV20 - Respiratory Syncytial Virus Infections | Phase 3 | Completed | GlaxoSmithKline | 1113 | 2023-05-26 | 2025-05-18 |
| Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) V116, PCV20 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2663 | 2022-07-13 | 2024-10-26 |
Pneumococcal Infections (3) · Pneumonia (2) · Respiratory Syncytial Virus Infections (1)
Vaxcyte, Inc. (2) · GlaxoSmithKline (1) · Merck Sharp & Dohme LLC (1)
United States (4) · Belgium (2) · Australia (1) · Chile (1) · Germany (1) · New Zealand (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1) · Turkey (Türkiye) (1)